Lymphoma News

NEW ORLEANS — A regimen containing post-transplant cyclophosphamide significantly lowered graft-versus-host disease risk among adults who underwent reduced-intensity allogeneic hematopoietic stem cell transplant, study results showed.

NEW ORLEANS — Consolidation therapy with high-dose chemotherapy followed by hematopoietic stem cell transplant significantly prolonged PFS among adults with primary central nervous system lymphoma, according to study results.

The addition of brentuximab vedotin and nivolumab to doxorubicin and dacarbazine appeared promising for adults with bulky stage II or stage III/stage IV classic Hodgkin lymphoma, according to study results.

ASH recognized three Choosing Wisely champions and three guideline implementation champions at this year’s ASH Annual Meeting and Exposition.

NEW ORLEANS — Patients recently treated with bendamustine had significantly lower response rates to subsequent chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma, data presented at ASH Annual Meeting and Exposition showed.

The FDA announced several regulatory actions the past few weeks.

This year’s ASH Annual Meeting and Exposition spotlighted practice-changing research in malignant and benign hematology.

The FDA granted accelerated approval to mosunetuzumab-axgb for treatment of adults with relapsed or refractory follicular lymphoma, the agency announced in a press release.

Speed matters when it comes to treatment of highly aggressive cancers.

NEW ORLEANS — Chimeric antigen receptor T cells demonstrated acceptable efficacy with no additional safety concerns when administered to patients with non-Hodgkin lymphoma and HIV, retrospective study results showed.